{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-013073","form_type":"8-K","ticker":"MXCT","cik":"0001287098","company_name":"MAXCYTE, INC.","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.282262+00:00","generated_at":"2026-06-24T01:20:46.474473+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MaxCyte Q2 revenue $9.6M (+35% YoY); raises 2022 core revenue growth guidance to ~30%","bullets":["Total revenue $9.6M (+35% YoY); core business revenue +45% led by cell therapy +61%.","Net loss $8.3M (vs $4.4M loss Q2 2021); operating expenses $17.2M (up from $10.7M).","Cash & investments $240.9M as of June 30, 2022.","Raised 2022 core revenue growth guidance to ~30%; SPL program-related revenue expected ~$4M.","Signed 17th SPL agreement in July 2022 with LG Chem."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-013073","json":"https://secwatch.observer/filing/0001558370-22-013073.json","markdown":"https://secwatch.observer/filing/0001558370-22-013073.md","text":"https://secwatch.observer/filing/0001558370-22-013073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287098/000155837022013073/0001558370-22-013073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287098/000155837022013073/mxct-20220810x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:20:46.474473+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}